Editas Medicine, Inc. is a clinical-stage genome-editing company based in Cambridge, Massachusetts. The company develops CRISPR-based medicines and holds exclusive rights to the Broad Institute's Cas12a patent estate, along with Cas9 patent estates from the Broad Institute and Harvard University for human medicines. Its lead program, EDIT-401, is an investigational in vivo gene-editing therapy aimed at treating hyperlipidemia by editing the LDLR gene to boost LDL receptor expression and lower LDL cholesterol. The company has also pursued programs in sickle cell disease and transfusion-dependent beta-thalassemia. I keep an eye on this name for its place in the gene-editing space and how its pipeline advances.
Editas Medicine shares have fallen substantially over the last 30 days. From a closing price of approximately $2.58 on October 20, 2026, the stock declined to $1.71 by November 19, 2026 — a drop of about 34%. The move was not linear: the stock briefly traded near $2.95 in late October before rolling over and sliding sharply in November. Over the last quarter, EDIT has fallen roughly 47%, from a mid-August level near $3.25 to its current level. This extends a sustained downtrend that reflects both company-specific strategic decisions and a challenging environment for speculative, pre-revenue biotechnology names. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The sharpest leg down followed Editas Medicine's third-quarter 2026 report, released on November 9. While the company beat consensus estimates — reporting a GAAP loss of $0.15 per share versus a $0.19 expected loss and revenue of $10.37 million versus a $4.49 million estimate — the market focused on strategy rather than the beat. Editas disclosed a strategic shift toward its in vivo EDIT-401 program, including the discontinuation of reni-cel, its investigational therapy for sickle cell disease and transfusion-dependent beta-thalassemia. The pivot raised questions about the company's pipeline breadth and drove a negative post-earnings reaction. Analyst commentary added to the pressure. RBC Capital reaffirmed a Hold rating with a $4.00 price target following the update, even as the broader sell-side consensus remained more constructive. The decline was amplified by sector-wide headwinds: rising Treasury yields, a risk-off tone across speculative healthcare, and pressure on gene-editing peers such as CRISPR Therapeutics (CRSP). Earlier in the period, a Wells Fargo upgrade to Overweight with a $6.00 target and Australian regulatory clearance to begin a Phase 1/2 study of EDIT-401 briefly supported the shares, but those gains were given back.
Over the last quarter, Editas Medicine's decline has been driven by a combination of strategic repositioning and persistent macro pressure. The company has narrowed its focus to EDIT-401 and its in vivo gene-editing platform, a shift that reduces near-term pipeline diversification while concentrating execution risk on a single lead program. Financing considerations also weigh on sentiment; Editas raised capital through a stock-and-warrant offering earlier in 2026, and investors remain attuned to the company's cash runway and potential for future dilution. Meanwhile, a broad rotation away from cash-burning biotech names — driven by higher interest rates and reduced risk appetite — has compounded the stock-specific drag. From what I see, this combination of internal and external factors explains much of the move.
Looking ahead, the key catalyst for Editas Medicine is clinical execution on EDIT-401. The company has indicated plans to begin patient dosing in the Phase 1/2 Strive study in 2026, with initial safety and tolerability data expected in the first quarter of 2027 and topline results from Part 1 anticipated in the second half of 2027. Investors will also monitor the company's cash position and any future financing activity, given its pre-revenue status. Broader factors — including interest-rate trends, biotech sector sentiment, and competitive developments across the gene-editing and lipid-lowering fields — are likely to influence the stock's path. Analyst expectations remain varied, with a consensus that skews positive but individual targets spanning a wide range. I’m watching this closely as the timeline unfolds.
I often turn to Tickeron’s AI tools when reviewing stocks like this one to get a sense of automated signals and patterns. The Trending AI Robots page highlights a curated selection of AI-powered trading bots that monitor various tickers and strategies. These bots cover different timeframes and approaches, offering a practical way to see how data-driven systems evaluate opportunities in names such as EDIT. It serves as a useful complement to traditional analysis without replacing personal judgment.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
EDIT saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 84 similar instances where the indicator turned negative. In 77 of the 84 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for EDIT turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 42 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
EDIT moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for EDIT moved below the 200-day moving average on November 09, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +7.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in 182 of 227 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
EDIT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 120 of 154 cases where EDIT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.
The Tickeron PE Growth Rating for this company is 32 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.749) is normal, around the industry mean (3.596). P/E Ratio (-3.894) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. EDIT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a company which translates genome editing technology into a novel class of human therapeutics
Industry Biotechnology